Needham & Company LLC Cuts Axon Enterprise (NASDAQ:AXON) Price Target to $600.00

Axon Enterprise (NASDAQ:AXON) had its price target decreased by Needham & Company LLC from $870.00 to $600.00 in a report released on Friday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biotechnology company’s stock.

Other equities analysts have also issued research reports about the stock. TD Cowen restated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. William Blair restated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 3rd. Wall Street Zen lowered Axon Enterprise from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Morgan Stanley dropped their target price on Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Finally, Northcoast Research upgraded Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price target for the company in a report on Tuesday, January 6th. Fifteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $786.43.

Axon Enterprise Stock Down 1.6%

Shares of NASDAQ:AXON opened at $433.91 on Friday. The stock has a 50-day simple moving average of $544.63 and a 200-day simple moving average of $634.72. The stock has a market capitalization of $34.24 billion, a P/E ratio of 137.31, a PEG ratio of 13.07 and a beta of 1.48. Axon Enterprise has a 1 year low of $396.41 and a 1 year high of $885.91. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12.

Insider Activity at Axon Enterprise

In other news, CAO Jennifer H. Mak sold 1,134 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $600.00, for a total transaction of $680,400.00. Following the completion of the transaction, the chief accounting officer directly owned 13,740 shares in the company, valued at approximately $8,244,000. This represents a 7.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeri Williams sold 100 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $550.63, for a total transaction of $55,063.00. Following the sale, the director directly owned 1,316 shares of the company’s stock, valued at $724,629.08. The trade was a 7.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 48,040 shares of company stock worth $27,249,338 over the last ninety days. Company insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Westside Investment Management Inc. grew its stake in Axon Enterprise by 4.8% in the second quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock worth $225,000 after purchasing an additional 13 shares in the last quarter. CVA Family Office LLC grew its position in shares of Axon Enterprise by 26.9% in the 2nd quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 14 shares in the last quarter. Newbridge Financial Services Group Inc. grew its position in shares of Axon Enterprise by 2.8% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock worth $421,000 after acquiring an additional 14 shares in the last quarter. Vicus Capital increased its holdings in shares of Axon Enterprise by 3.7% in the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 14 shares during the last quarter. Finally, Evergreen Capital Management LLC raised its position in shares of Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after acquiring an additional 15 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

More Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Needham kept a Buy rating and cites strong bookings momentum and an expanding ecosystem, supporting medium-term growth expectations. Axon: Strong Bookings Momentum and Expanding Ecosystem Drive Sustained Growth and Buy Rating
• Positive Sentiment: Recent market-coverage pieces highlighted a trading-day gain (a prior session rise of ~2.6%), showing there remains near-term buying interest on positive news flow. Why the Market Dipped But Axon Enterprise (AXON) Gained Today
• Neutral Sentiment: Wall Street projections for AXON’s Q4 (Dec‑2025) revenues, bookings and margins are now widely circulated; these estimates will drive the next big move when quarterly results and guidance arrive. Insights Into Axon (AXON) Q4: Wall Street Projections for Key Metrics
• Neutral Sentiment: Several “trending” and company‑profile summaries are circulating, increasing retail attention but not adding new fundamental catalysts by themselves. Axon Enterprise, Inc (AXON) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Reported short‑interest data in the feeds appears to be erroneous/zeroed out (no actionable signal); ignore until accurate figures are posted by exchanges.
• Negative Sentiment: Multiple insiders sold about US$43M of AXON stock recently — a near‑term negative for sentiment as investors often view sizeable insider selling as cautionary. Axon Enterprise Insiders Sell US$43m Of Stock, Possibly Signalling Caution
• Negative Sentiment: Needham lowered its price target from $870 to $600 — while the Buy rating remains, the reduced target trims upside and can weigh on investor sentiment and momentum. Benzinga Coverage of Needham Price Target Change

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.